{"id":"W2587429794","doi":"10.1016/s1470-2045(17)30072-4","title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":206,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Merck Sharp and Dohme; Bristol-Myers Squibb","keywords":"Vismodegib; Medicine; Basal cell carcinoma; Regimen; Placebo; Internal medicine; Population; Dosing; Basal Cell Nevus Syndrome; Oncology; Urology; Pathology; Basal cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001439368,0.002319395,0.003861579,0.00058212,0.0004993562,0.001316798,0.001073739,0.002263439,0.009724824],"category_scores_gemma":[0.001574866,0.0009370971,0.00240291,0.0004934542,0.001347703,0.001833032,0.0005808926,0.004436692,0.001609681],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001048038,"about_ca_system_score_gemma":0.0008972394,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001064601,"about_ca_topic_score_gemma":0.002644497,"domain_scores_codex":[0.9994588,0.0002056306,0.00003033613,0.0001346075,0.00004056226,0.000130033],"domain_scores_gemma":[0.9993027,0.0001701752,0.0001263996,0.00008592365,0.0000360312,0.0002787909],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9731668,0.004574689,0.0003389173,0.000443594,0.0007844961,0.00002261842,0.00004883063,0.0003555324,0.002166886,0.0001133281,0.0007098608,0.01727461],"study_design_scores_gemma":[0.959994,0.03815752,0.0007318112,0.00002189707,0.0002063959,0.00001870701,0.00001725174,0.0001761049,0.0001692627,0.0001303475,0.0003639504,0.00001262922],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847785,0.00514671,0.0009078854,0.001028317,0.0007790999,0.003409602,0.001195553,0.0001962859,0.002558008],"genre_scores_gemma":[0.9778476,0.003724819,0.002220498,0.001966007,0.0005294043,0.005538343,0.00155438,0.00005591274,0.006563004],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009724824,"threshold_uncertainty_score":0.03253281,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0508492730864267,"score_gpt":0.339065832435165,"score_spread":0.2882165593487384,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}